Efficacy and Safety of Everolimus with Reduced Tacrolimus Compared to Standard Tacrolimus in Recipients of Living Donor Liver Transplant: Design of a Randomized Study.
D. Grant,G. Levy,G. Song,C. Chen,W. Lee,J. Joh,A. Speziale,B. Rauer,Z. Wang,G. Junge,S. Uemoto,K. Suh
DOI: https://doi.org/10.1097/00007890-201407151-02673
2014-01-01
Transplantation
Abstract:Purpose: Living donor liver transplantation (LDLT) is an attractive approach to address deceased donor shortage and increasing demand. However, data from randomized clinical studies evaluating effect of different immunosuppressive regimens in LDLT recipients is sparse. Here we present the design of H2307 study, the first study to evaluate efficacy and safety of everolimus (EVR) with reduced tacrolimus (rTAC) vs. standard TAC control (TAC-C) in LDLT recipients. Methods: H2307 is a 24-month (M), multicenter, randomized, controlled study planned to enroll at least 470 LDLT recipients (male and female, ≥18 years). To allow for optimal allograft regeneration and wound healing, patients enter a 30-day run-in period with TAC (8-12ng/mL) ± mycophenolate mofetil ± anti-IL2 induction and steroids before stratified randomization (RND) in a 1:1 ratio to receive EVR (C0 3-8ng/mL) + rTAC (C0 3-5ng/mL) or TAC-C (6-10ng/mL) (Figure 1). Stratification is based on hepatocellular carcinoma (HCC) at time of LT. Main inclusion criteria include: 1) HIV negative status and 2) known HCV and HBV status. Exclusion criteria include: 1) HCV negative subjects receiving transplant from HCV positive donor, 2) MELD score >35 within 1M prior to transplantation, and 3) HCC patients with extra-hepatic spread or macrovascular invasion. Study objectives include composite efficacy failure of treated biopsy-proven acute rejection, graft loss or death as well as evolution of renal function from RND to M12 and M24, and incidence of adverse events. Specific objectives include incidence and time to HCC recurrence, evolution of HCV viral load, and allograft regeneration. Results: The study will be run at 41 centers across 11 countries. 12M results are expected in 2016. Conclusion: For the first time, a randomized, multicenter study is performed in a large cohort of LDLT recipients, comparing the efficacy and safety of EVR+rTAC vs. TAC-C.Figure: No Caption available.DISCLOSURES:Levy, G.: Speaker's Bureau, Novartis, Astellas, Abott. Speziale, A.: Employee, Novartis. Rauer, B.: Employee, Novartis. Wang, Z.: Employee, Novartis. Junge, G.: Employee, Novartis. Uemoto, S.: Other, Novartis, Advisory committee.